Kwality Pharmaceuticals has informed that the company has successfully concluded a regulatory audit for Zimbabwe across its General, Beta-Lactam, Cephalosporin and Oncology units, with no critical observations. This marks yet another milestone in its series of successful audits over the past year.
The above information is a part of company’s filings submitted to BSE.